Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Blood

• Publication date

  1996-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V88.10.4063.BLOODJOURNAL88104063PMID 8916975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.

  1996cited by this paper
• Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

  1995cited by this paper
• Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.

  1995influential reference
• Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [letter]

  1994cited by this paper
• Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention.

  1994cited by this paper
• Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

  1994cited by this paper
• Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes

  1994cited by this paper
• Early detection and treatment of cytomegalovirus infections in marrow transplant patients: methodological aspects and implications for therapeutic interventions.

  1994cited by this paper
• Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients

  1994cited by this paper
• Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia.

  1994cited by this paper
• Factors influencing detection of quantitative cytomegalovirus antigenemia

  1994cited by this paper
• Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

  1993cited by this paper
• Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods

  1993cited by this paper
• EARLY DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS BY DNA AMPLIFICATION IN PLASMA

  1993cited by this paper
• Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind Trial

  1993cited by this paper
• Diagnosis of cytomegalovirus pneumonia by the polymerase chain reaction with archived frozen lung tissue and bronchoalveolar lavage fluid.

  1993cited by this paper
• Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients.

  1992cited by this paper
• Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia

  1992cited by this paper
• Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation.

  1992cited by this paper
• Direct detection of cytomegalovirus in peripheral blood leukocytes--a review of the antigenemia assay and polymerase chain reaction.

  1992cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Genital human papillomavirus infection in female university students as determined by a PCR‐based method

  1991cited by this paper
• Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia.

  1991cited by this paper
• Producing single-stranded DNA probes with the Taq DNA polymerase: a high yield protocol.

  1991cited by this paper
• Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia.

  1991cited by this paper
• Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.

  1991cited by this paper
• Comparison of MRC-5 and U-373MG astrocytoma cells for detection of cytomegalovirus in shell vial centrifugation cultures

  1991cited by this paper
• A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants

  1991cited by this paper
• Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique.

  1991cited by this paper
• Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation.

  1991cited by this paper
• A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

  1991cited by this paper
• Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.

  1991influential reference
• Inhibition of immune functions by antiviral drugs.

  1991cited by this paper
• Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins

  1990cited by this paper
• Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.

  1990cited by this paper
• Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.

  1990cited by this paper
• Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients.

  1989cited by this paper
• Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

  1988cited by this paper
• Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses.

  1987cited by this paper
• Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens

  1985cited by this paper
• Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

  1982cited by this paper
• Sample size requirements for evaluating a conservative therapy.

  1978cited by this paper

• Development and Validation of a Liquid Chromatograph-Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring.

  2026cites this paper
• Risk factors of cytomegalovirus reactivation in patients with rheumatic musculoskeletal diseases undergoing remission induction therapy with high-dose glucocorticoids; a prospective short-term cohort study

  2025cites this paper
• Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era

  2025cites this paper
• Risk-adapted letermovir prophylaxis based on a scoring system predicting a higher burden of cytomegalovirus exposure after allogeneic hematopoietic cell transplantation.

  2025cites this paper
• Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

  2025cites this paper
• Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

  2024cites this paper
• Application of CMV‐IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients

  2024cites this paper
• Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

  2024cites this paper
• Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease

  2024cites this paper
• Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation

  2024cites this paper
• CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia

  2023cites this paper
• Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.

  2023cites this paper
• M‐CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation

  2023cites this paper
• Once Daily Foscarnet is Effective for HHV-6 Reactivation after Hematopoietic Stem Cell Transplantation.

  2023cites this paper
• Unforeseen cytomegalovirus retinopathy following high dose thiotepa and proton irradiation in a pediatric patient with high-risk medulloblastoma: A case report

  2023cites this paper
• Research progress of purine competitive antagonists.

  2022cites this paper
• Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation

  2022cites this paper
• Factors associated with cytomegalovirus antigenemia in patients with rheumatic disease: A retrospective study.

  2022cites this paper
• Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplant recipients following letermovir prophylaxis.

  2022cites this paper
• The changing impact of cytomegalovirus among hematopoietic cell transplant recipients during the past decade: A single institutional cohort study

  2022cites this paper
• Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation – A retrospective single‐center study

  2022cites this paper
• Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation

  2022cites this paper
• Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression.

  2022cites this paper
• Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy

  2022cites this paper
• Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis

  2022cites this paper
• Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy.

  2021cites this paper
• Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease

  2021cites this paper
• Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

  2021cites this paper
• Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation

  2021cites this paper
• Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis.

  2021cites this paper
• Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients

  2021cites this paper
• Prediction of CMV reactivation by recipient CMV-IgG titer before allo-HCT.

  2021cites this paper
• Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

  2021cites this paper
• A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

  2021cites this paper
• Are hematopoietic cell transplant recipients with Gram‐negative bacteremia spending more time outpatient while on intravenous antibiotics? Addressing trends over 10 years at a single center

  2021cites this paper
• Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation Transplantation and Cellular Therapy

  2021cites this paper
• Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.

  2021cites this paper
• Risk factors for cytomegalovirus reactivation in patients with kidney disease under immunosuppressive therapy

  2021cites this paper
• Every-Other-Day Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Kidney Transplant Recipients: A Single-Center Experience

  2021cites this paper
• Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation

  2021cites this paper
• Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment

  2020cites this paper
• How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

  2020cites this paper
• Impact of anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors.

  2020cites this paper
• Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

  2020cites this paper
• Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation

  2020cites this paper
• A Case of Cytomegalovirus-Induced Oral Ulcer in an Older Adult Patient with Nephrotic Syndrome due to Membranous Nephropathy

  2020cites this paper
• How I Treat MAJOR COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

  2020cites this paper
• Letermovir Prophylaxis Decreases Burden of CMV in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.

  2020cites this paper
• Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients

  2020cites this paper
• Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality.

  2020cites this paper
• Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data

  2020cites this paper
• Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for hematological disease: systematic review and meta-analysis.

  2020cites this paper
• Low-level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen Specific T-Cells after Allogeneic Hematopoietic Cell Transplantation.

  2020cites this paper
• Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

  2019cites this paper
• Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.

  2019cites this paper
• Capsule Endoscopy after Hematopoietic Stem Cell Transplantation Can Predict Transplant-Related Mortality

  2019cites this paper
• High-resolution analysis of human cytomegalovirus-specific T-cell receptor repertoires

  2019cites this paper
• Risk-stratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants

  2019cites this paper
• Ganciclovir pre‐emptive therapy for cytomegalovirus antigenemia in a pemphigus vulgaris patient

  2019cites this paper
• A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients

  2019cites this paper
• [Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies].

  2019cites this paper
• Aktualitások a sérült immunitású betegek cytomegalovirusinfekcióinak ellátásában II. Terápiás lehetőségek és ellátási stratégiák patients with cytomegalovirus

  2019cites this paper
• Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

  2019cites this paper
• Antimicrobial Prophylaxis and Preemptive Approaches for the Prevention of Infections in the Stem Cell Transplant Recipient, with Analogies to the Hematologic Malignancy Patient.

  2019cites this paper
• Cytomegalovirus

  2019cites this paper
• Early cytomegalovirus reactivation and expansion of CD56brightCD16dim/-DNAM1+ natural killer cells are associated with anti-leukemia effect after haploidentical stem cell transplantation in acute leukemia.

  2019cites this paper
• Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients

  2019cites this paper
• Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.

  2019cites this paper
• Host and Graft Factors Impacting Infection Risk in Hematopoietic Cell Transplantation.

  2019cites this paper
• Prophylaxis and Management of Infectious Complications After Hematopoietic Cell Transplantation

  2019cites this paper
• Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.

  2018cites this paper
• The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data

  2018cites this paper
• Epidemiology and risk factors for cytomegalovirus infection in glomerular diseases treated with immunosuppressive therapy

  2018cites this paper
• Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant

  2018cites this paper
• Infections in Hematopoietic Stem Cell Transplant Recipients

  2018cites this paper
• Molecular Monitoring of Viral Infections

  2018cites this paper
• Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.

  2018cites this paper
• Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting.

  2018cites this paper
• Impacts and Challenges of Advanced Diagnostic Assays for Transplant Infectious Diseases

  2018cites this paper
• Management of Infections in the Immunocompromised Host

  2018cites this paper
• Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients

  2018cites this paper
• Effects on tumor immunity, liver, gut, lung and survival after cutaneous graft-versus-host disease regulated by photochemotherapy

  2018cites this paper
• Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation

  2018cites this paper
• Impact of cytomegalovirus DNAemia on overall and non‐relapse mortality in allogeneic stem cell transplant recipients

  2017cites this paper
• Haploidentical Stem Cell Transplantation

  2017influential citation
• TRANSPLANTATION Brincidofovir is highly ef fi cacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant

  2017cites this paper
• Diagnosis of Viral Infections

  2017influential citation
• Nouvelles perspectives thérapeutiques dans l’infection à cytomégalovirus

  2017cites this paper
• Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia

  2017cites this paper
• Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients

  2017cites this paper
• Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options

  2017cites this paper
• Prevention and Treatment of Infectious Complications in Haploidentical SCT

  2017cites this paper
• Cytomegalovirus Infection in the Era of Preemptive Strategy in Allogeneic Hematopoietic Cell Transplant Recipients: Progression From Viremia to Disease Remains Rare But Unpredictable

  2017cites this paper
• Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma

  2017cites this paper
• Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infection-systematic review and meta-analysis.

  2017cites this paper
• Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant.

  2017cites this paper
• Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

  2017cites this paper
• Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies

  2017cites this paper
• Early abnormal liver enzyme levels may increase the prevalence of human cytomegalovirus antigenaemia after hematopoietic stem cell transplantation

  2017cites this paper